Latest United States News

Delegat Group delivered record operating earnings and cash flow in FY26, but reported profit fell after a NZ$8.7 million impairment and other fair-value adjustments. The NZX-listed wine company is forecasting higher case sales and operating NPAT of NZ$62 million to NZ$66 million for FY27.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

Ardea Resources enters FY2027 with its flagship Goongarrie Hub still short of a completed definitive feasibility study, even as Japanese partners and governments deepen their support. The company reported a A$24.6 million consolidated loss, while future funding arrangements beyond the current DFS program remain unresolved.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Nico Resources is advancing drilling, metallurgical studies and a potential downstream battery-materials partnership at Wingellina, despite a subdued nickel market and a larger annual loss. The company ended FY2026 with $4.73 million across cash and short-term investments after raising $3.73 million in equity.

GCM Corporation’s FY26 report charts its shift from explorer to thermal-management manufacturer, with independent VHD validation, 44 products and first reported product sales. But the company remains loss-making, cash-burning and dependent on further funding, while its auditor warns of material uncertainty over going concern.

Victory Metals has set out a 20-year development case for North Stanmore, backed by a 47 million tonne Probable Ore Reserve and a pre-tax NPV8 of A$1.76 billion. The project remains pre-feasibility stage, while the company ended FY2026 with A$11.18 million in cash and no operating revenue.

Memphasys says it has identified a potential FDA 510(k) pathway for its Felix sperm separation system, replacing the more complex De Novo route previously contemplated. The company will seek FDA feedback before targeting a formal submission in the first quarter of 2027, while keeping commercial execution focused on existing markets.

SkinKandy Limited (ASX:SK1) exceeded its IPO forecasts in FY26, with pro forma revenue rising 29% to A$90.2 million and pro forma NPAT climbing 41% to A$9.0 million. The newly listed retailer enters FY27 with 115 stores, 11 approved leases and plans for potential expansion into South Africa and the United States.

EcoGraf has strengthened the technical and commercial case for its Tanzanian graphite strategy, including a larger Epanko ore reserve and planned downstream processing. But cash fell to A$3.8 million, and auditors flagged a material uncertainty over the company’s ability to continue as a going concern.

Kelsian Group delivered record FY26 earnings and lifted its fully franked dividend, while preparing to become a more focused bus, coach and ferry operator. The next test is execution: completing the conditional tourism sale, mobilising new contracts and delivering against FY27 EBITDA guidance.

Cobalt Blue has cleared important technical and regulatory hurdles at its Kwinana refinery, but the pre-revenue developer says further funding is needed and auditors flagged material uncertainty over its ability to continue as a going concern. The company reported an A$8.797 million loss for FY2026 despite ending the year with A$4.265 million in cash.